HIV-1 Cellular Immunity in Exposed Seronegatives

暴露的血清阴性者中的 HIV-1 细胞免疫

基本信息

项目摘要

DESCRIPTION (provided by applicant): We wish to gain insight into the immune correlates of HIV protection by investigating potential mechanisms of HIV-1 resistance among high-risk, multiply exposed, seronegative (ES) individuals. Employing standardized assays and incorporating relevant control groups for comparative analyses, we found that most persons in the Seattle ES cohort lack HIV-1-specific IFN-gamma-secreting T cell responses. Moreover, their levels of CD4+ T cell infectivity with either R5- or X4-dependent viruses are similar to those in the lower risk control population. However, clear individual exceptions exist, and the fate of some ES over time has become quite intriguing. Some have seroconverted with viruses distinct from their known long-term infected sexual partners. Others remain seronegative but upon careful examination bear extremely low copy numbers of HIV-1 DNA. These results suggest that rare members within this cohort may have an unusual capacity to control HIV-1 infection that is distinct from CCR5 coreceptor impairment. We propose 3 specific aims to test the overall hypothesis that some long-term, multiply exposed seronegative persons have relative resistance to HIV infection that is maintained by their immune response. In Aim 1, we will ascertain and compare the frequency and reproducibility of HIV-1-specific IL-2- and IFN-gamma-secreting T cell responses in ES among different sexually-exposed risk groups. In Aim 2, we will assess the complete repertoire of anti-viral cellular responses in ES using multiparameter flow cytometry and array technology. In Aim 3, we will determine the contribution of HIV-1-specific T cell responses in ES who have unusual control of HIV-1 infection, either maintaining seronegativity with very low HIV-1 levels or following late seroconversion. We will conduct investigations in geographically diverse seronegative populations whose viral subtype and route of exposure differ: 1) MSM from the Seattle ES cohort, exposed to subtype B HIV-1; 2) high HIV risk MSM participants of HPTN Protocol 039 in Seattle and Peru, exposed to subtype B HIV-1, and 3) high risk heterosexual women and men from three cohort studies in cDurban, Republic of South Africa, exposed to subtype C HIV-1. The results will inform our decisions of the specific assays to employ in vaccine trials, guide interpretation of responses in trial participants with high-risk activities in HIV endemic areas, and potentially invoke new concepts for vaccine design and correlates of protection.
描述(由申请人提供):我们希望通过研究高风险、多重暴露、血清阴性(ES)个体中HIV-1耐药性的潜在机制,深入了解HIV保护的免疫相关因素。采用标准化分析并纳入相关对照组进行比较分析,我们发现西雅图ES队列中的大多数人缺乏hiv -1特异性ifn - γ分泌T细胞反应。此外,他们的CD4+ T细胞感染R5或x4依赖性病毒的水平与低风险控制人群相似。然而,存在明显的个别例外,并且随着时间的推移,一些ES的命运变得相当有趣。有些人血清转化的病毒不同于他们已知的长期感染的性伴侣。其他人仍然是血清阴性,但经过仔细检查,HIV-1 DNA拷贝数极低。这些结果表明,该队列中的罕见成员可能具有不同于CCR5共受体损伤的控制HIV-1感染的不寻常能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Margaret Juliana McElrath其他文献

Margaret Juliana McElrath的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Margaret Juliana McElrath', 18)}}的其他基金

CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
CoVPN 3003 评估 Ad26.COV2.S 在 18 岁及以上成年人中预防 SARS-CoV-2 介导的 COVID-19 的功效和安全性的 3 期研究 LC 3
  • 批准号:
    10570748
  • 财政年份:
    2022
  • 资助金额:
    $ 58.46万
  • 项目类别:
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
HVTN 405/HPTN 1901 (CoVPN) 表征恢复期个体的 SARS-CoV-2 特异性免疫:LC 3
  • 批准号:
    10570806
  • 财政年份:
    2022
  • 资助金额:
    $ 58.46万
  • 项目类别:
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Lab
CoVPN 3004 - 一项 3 期随机、观察者盲法、安慰剂对照研究,旨在评估 SARS-CoV-2 重组刺突蛋白纳米颗粒疫苗实验室的功效、安全性和免疫原性
  • 批准号:
    10322580
  • 财政年份:
    2021
  • 资助金额:
    $ 58.46万
  • 项目类别:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
HVTN 405/HPTN 1901 表征恢复期个体的 SARS-CoV-2 特异性免疫力:LC
  • 批准号:
    10165321
  • 财政年份:
    2020
  • 资助金额:
    $ 58.46万
  • 项目类别:
SARS-CoV-2 testing at the Seattle Vaccine and Prevention CRS (30331)
西雅图疫苗和预防 CRS 进行 SARS-CoV-2 检测 (30331)
  • 批准号:
    10166485
  • 财政年份:
    2020
  • 资助金额:
    $ 58.46万
  • 项目类别:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core
对疟疾、HIV 和 SARS-CoV-2 感染和免疫的免疫反应 - 临床核心
  • 批准号:
    10419582
  • 财政年份:
    2017
  • 资助金额:
    $ 58.46万
  • 项目类别:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization
对疟疾、HIV 和 SARS-CoV-2 感染的免疫反应和免疫接种
  • 批准号:
    10419580
  • 财政年份:
    2017
  • 资助金额:
    $ 58.46万
  • 项目类别:
Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection
科学项目 2:HIV AIDS 定义人类接种疫苗后的分子特征,为针对 HIV-1 感染的保护性免疫途径提供信息
  • 批准号:
    10419585
  • 财政年份:
    2017
  • 资助金额:
    $ 58.46万
  • 项目类别:
Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core
对疟疾和艾滋病毒感染的免疫反应和免疫接种 - 临床核心
  • 批准号:
    10198679
  • 财政年份:
    2017
  • 资助金额:
    $ 58.46万
  • 项目类别:
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core
对疟疾、HIV 和 SARS-CoV-2 感染和免疫的免疫反应 - 临床核心
  • 批准号:
    10631089
  • 财政年份:
    2017
  • 资助金额:
    $ 58.46万
  • 项目类别:

相似海外基金

A targeted combination intervention approach for acute HIV infections to curb the explosive epidemic among high-risk populations in Indonesia
针对急性艾滋病毒感染的针对性组合干预方法,遏制印度尼西亚高危人群的爆发性流行
  • 批准号:
    MR/V035304/1
  • 财政年份:
    2022
  • 资助金额:
    $ 58.46万
  • 项目类别:
    Research Grant
IMPAACT RELATED PROTOCOLS FOR THE RESEARCH ON TREATMENT, PREVENTION, DIAGNOSIS AND EPIDEMIOLOGY OF HIV INFECTIONS
HIV 感染的治疗、预防、诊断和流行病学研究的影响相关方案
  • 批准号:
    10369859
  • 财政年份:
    2021
  • 资助金额:
    $ 58.46万
  • 项目类别:
Determining the mechanisms of vascular CD8 T cell activation in CMV and HIV infections
确定 CMV 和 HIV 感染中血管 CD8 T 细胞激活的机制
  • 批准号:
    10461964
  • 财政年份:
    2021
  • 资助金额:
    $ 58.46万
  • 项目类别:
Determining the mechanisms of vascular CD8 T cell activation in CMV and HIV infections
确定 CMV 和 HIV 感染中血管 CD8 T 细胞激活的机制
  • 批准号:
    10326617
  • 财政年份:
    2021
  • 资助金额:
    $ 58.46万
  • 项目类别:
Combination HIV Prevention: Using anti-retroviral and anti-inflammatory medications to prevent new HIV infections
HIV 联合预防:使用抗逆转录病毒和抗炎药物预防新的 HIV 感染
  • 批准号:
    404211
  • 财政年份:
    2018
  • 资助金额:
    $ 58.46万
  • 项目类别:
    Operating Grants
BALTIMORE: PROJECTS TO REDUCE HIV INFECTIONS AND IMPROVE ENGAGEMENT IN HIV MEDICAL CARE AMONG MSM
巴尔的摩:减少艾滋病毒感染和提高男男性行为者参与艾滋病毒医疗护理的项目
  • 批准号:
    9078083
  • 财政年份:
    2015
  • 资助金额:
    $ 58.46万
  • 项目类别:
Health Department Demonstration Projects to Reduce HIV Infections and Improve Engagement in HIV Medical Care among Men Who Have Sex with Men (MSM) and Transgender Persons
卫生部示范项目旨在减少男男性行为者 (MSM) 和跨性别者的艾滋病毒感染并提高他们对艾滋病毒医疗护理的参与度
  • 批准号:
    9079323
  • 财政年份:
    2015
  • 资助金额:
    $ 58.46万
  • 项目类别:
REDUCING HIV INFECTIONS AND IMPROVING ENGAGEMENT IN HIV MEDICAL CARE AMONG MSM IN MEMPHIS TN
减少田纳西州孟菲斯市 MSM 的 HIV 感染并提高其对 HIV 医疗护理的参与度
  • 批准号:
    9079336
  • 财政年份:
    2015
  • 资助金额:
    $ 58.46万
  • 项目类别:
Double-Negative T cells in SIV and HIV Infections
SIV 和 HIV 感染中的双阴性 T 细胞
  • 批准号:
    8472130
  • 财政年份:
    2012
  • 资助金额:
    $ 58.46万
  • 项目类别:
REDUCING HIV INFECTIONS AMONG COMMERCIAL SEX WORKERS IN GERT SIBANDE DISTRICT TAV
减少格特西班德区 TAV 商业性工作者的艾滋病毒感染
  • 批准号:
    8532661
  • 财政年份:
    2011
  • 资助金额:
    $ 58.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了